Anacor Pharmaceuticals, Inc.

Amazentis Sa

Cytokinetics, Inc.

Global Blood Therapeutics, Inc.

Irix Pharmaceuticals, Inc.

Smithkline Beecham Corporation

Cylene Pharmaceuticals, Inc.

Resverlogix Corporation

Patheon Api Services Inc.

Lund Biotechnology Pbc

George Yiannikouros

Panos Kalaritis

Christopher Goss

Jacob J Plattner

Yong-Kang Zhang

Tsutomu Akama

Kirk R Maples

Vincent S Hernandez

Virginia J Sanders

Stephen J Baker

Michael Richard Kevin Alley

Wolfgang Skranc

Karin M Hold

Fernando Rock

Huchen Zhou

Igor Likhotvorik

Chaminda Priyapushpa Gamage

Michael DiPierro

Isaac Kennedy

Alexander Trofimov

Weimin Mao

Aaron M Stemphoski

Zhixing Shan

Zhe Li

Stephen J Benkovic

Nathan Guz

Siead Zegar

Yiyang Shao

Denis Viktorovich Arefyev

Markus Frieser

Julieana Cocuz

Liang Liao

Bradley Paul Morgan

Michael E Jung

Jeffrey Paul Whitten

Gustave Bergnes

Fabrice Pierre

Michael Schwaebe

Henrik C Hansen

Michael Paul Cruskie, Jr

Collin Regan

Edward HyungSuk Ha

Shubham P Chopade

Janakiram Rao Citineni

Brandon E Yonce

Kurt Alan Welday, Jr

Siead Zagar

Stephanie Bosse Abernathy

Robert P Short

Steven J Benkovic

Denis Arefyev

Methods for preparing a salt of urolithin A and, in turn, urolithin A. Combining in an alkaline aqueous solution a copper-containing catalyst, 2-bromo-5-hydroxybenzoic acid, and resorcinol produces a salt of urolithin A. Urolithin A has been prepared by protonating a salt of the compound.

Process-scale synthesis of urolithin A

Disclosed are methods for preparing a salt of urolithin A and, in turn, urolithin A. The methods are advantageous for the large-scale preparation of urolithin A or a pharmaceutically acceptable salt thereof.

Disclosed herein are processes for synthesizing 2-hydroxy-6-((2-(1-isopropyl-1H-pyrazol-5-yl)-pyridin-3-yl)methoxy)benzaldehyde (also referred to herein as Compound (I)) and intermediates used in such processes. Compound (I) binds to hemoglobin and increases it oxygen affinity and hence can be useful for the treatment of diseases such as sickle cell disease.

Process for synthesizing 2-hydroxy-6-((2-(1-isopropyl-1H-pyrazol-5-yl)-pyridin-3-yl)methoxy)benzaldehyde

Methods of synthesizing prostaglandins, prostaglandin analogs and their synthetic intermediates are described. The methods can comprise metal-catalyzed metathesis reactions. Also provided are synthetic intermediates that can be used in the synthesis of the prostaglandins and prostaglandin analogs.

Synthesis routes for prostaglandins and prostaglandin intermediates using metathesis

The presently disclosed subject matter provides methods of preparing synthetic prostacyclin analogs, including Beraprost, either as racemic mixtures or as single stereoisomers. Also provided are novel synthetic intermediates for use in these methods.

Process for preparing synthetic prostacyclins

This invention relates to compounds useful for treating fungal infections, more specifically topical treatment of onychomycosis and/or cutaneous fungal infections. This invention is directed to compounds that are active against fungi and have properties that allow the compound, when placed in contact with a patient, to reach the particular part of the skin, nail, hair, claw or hoof infected by the fungus. In particular the present compounds have physiochemical properties that facilitate penetration of the nail plate.

Boron-containing small molecules

The presently disclosed subject matter provides a method of synthesizing prostaglandins and prostaglandin analogs comprising the ring closing metathesis of compounds of Formula (I). Also provided are novel compounds of Formula (I) and Formula (II). In addition to their use as synthetic intermediates in the presently disclosed methods, compounds of Formula (II) can be used as prostaglandin and/or prostaglandin analog prodrugs.

Synthesis of prostanoids

A method of preparing a N-acyl-N,N',N&#x2032;-alkylenediamine trialkanoic acid ester comprising contacting a cyclic amidine with an ester of a haloalkanoic acid is provided. In some embodiments, the method involves preparing a N-acyl-N,N&#x2032;,N&#x2032;-ethylenediamine trialkanoic acid ester by contacting a 2-alkyl imidazoline with the ester of haloalkanoic acid. In some embodiments, the N-acyl-N,N&#x2032;,N&#x2032;-alkylenediamine trialkanoic acid ester is a synthetic intermediate in the preparation of a N-acyl-N,N&#x2032;,N&#x2032;-alkylenediamine trialkanoic acid or a salt thereof. In some embodiments, the method provides novel N-acyl-N,N&#x2032;,N&#x2032;-alkylenediamine trialkanoic acids and/or esters, which can be used, for example, as chelating agents.

N-alkanoyl-N,N',N&#x2032;-alkylenediamine trialkanoic acid esters

The present disclosure relates to methods for preparing compounds, which are useful for regulating the expression of apolipoprotein A-I (ApoA-I), and in the treatment and prevention of cardiovascular disease and related disease states, including cholesterol- or lipid-related disorders, such as, for example, atherosclerosis. 

Methods of preparing quinazolinone derivatives

The present invention relates to methods of preparing compounds having formula (1), (2), (5), and ((6A)-(6D)) 

Methods for converting quinolone esters into quinolone amides

The present invention provides intermediates, synthetic methods and novel urea compositions of matter.

Syntheses of ureas

Growing community of inventors

Florence, SC, United States of America

George Yiannikouros